
CereGate closed an oversubscribed Series C led by an unnamed global US medtech company. The Munich-based company develops software that delivers personalized stimulation through existing deep brain stimulation implants, initially targeting freezing of gait in Parkinson's disease. Its software runs on Boston Scientific systems and has been tested in more than 85 participants. The funding amount was not disclosed.